Aidoc has received FDA clearance for what it describes as healthcare’s first comprehensive AI triage solution powered by a foundation model, marking a significant shift in how AI is deployed across radiology workflows. The clearance brings 11 newly approved acute indications, combined with three previously cleared ones, into a single body CT triage workflow. Built on Aidoc’s CARE™ foundation model and delivered through its aiOS™ enterprise platform, the solution is designed to surface critical findings earlier—particularly in crowded emergency departments and imaging backlogs, where first-in–first-out reading can delay urgent diagnoses.
Author: Abhay Panchal
NYU Langone Health announced the appointment of Anirban Maitra, MD, a preeminent physician–scientist whose work has widely influenced the field of pancreatic cancer research, as the new director of the Laura and Isaac Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center. Before joining NYU Langone, Dr. Maitra served as the inaugural scientific director of the Pancreatic Cancer Research Center at the University of Texas MD Anderson Cancer Center in Houston. Dr. Maitra’s work focused on early detection and biomarker development, two key avenues for effective cancer treatments. After serving in a number of leadership roles at MD Anderson, he was…
The Colorectal Cancer Alliance has launched CLEAR for CRC, a patient-centered initiative designed to close persistent gaps in early biomarker testing for newly diagnosed colorectal cancer—particularly for patients with advanced or metastatic disease. Biomarker testing helps identify a tumor’s molecular profile, guiding treatment selection, eligibility for targeted therapies, and access to clinical trials. Despite its clinical importance, testing remains inconsistently ordered, often delayed until after first-line therapy, or missed entirely—especially in rural and underserved communities. CLEAR for CRC addresses these gaps through three core strategies: The initiative is led by Dr. Erin Siegel, principal investigator of the CLEAR for CRC…
GRAIL has submitted the final module of its FDA Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test, moving the test one step closer to potential regulatory approval and broader clinical adoption in the U.S. The PMA submission is anchored in data from two of the largest MCED studies to date: the PATHFINDER 2 U.S. registrational study and the NHS-Galleri randomized controlled trial in England. Together, these trials evaluate Galleri’s safety, performance, and real-world diagnostic pathways when used alongside standard cancer screening.
A prospective multicenter study published in Therapeutic Advances in Gastrointestinal Endoscopy evaluated whether colon capsule endoscopy (CCE) could serve as a practical alternative for FIT-positive individuals who are unable or unwilling to undergo colonoscopy within a national colorectal cancer screening program. While CCE demonstrated a high per-patient polyp detection rate (77% for lesions ≥6 mm), real-world feasibility proved limited. More than half of eligible FIT-positive patients were excluded due to comorbidities or contraindications, bowel preparation quality was adequate in fewer than 40% of cases, and only 69% of procedures were complete within battery life. Importantly, most patients still required follow-up…
Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries found. The study was published in JAMA Network Open and was led by researchers from New Haven, Conn.-based Yale University and the University of California Los Angeles. They analyzed 24,973,642 commercially insured beneficiaries ages 50-75 from 2017 to 2024. About half were women, and nearly one-third received at least one colorectal cancer screening test during the study period.
Olympus Corporation of the Americas has announced the U.S. launch of SecureFlex™, its newest single-use fine needle biopsy (FNB) device designed for endoscopic ultrasound–guided tissue sampling, particularly in challenging anatomies such as the pancreatic head and uncinate process. The SecureFlex FNB needle is engineered to collect larger, intact tissue samples, addressing growing diagnostic needs in pancreatic cancer as molecular profiling and targeted therapies increasingly depend on high-quality histologic specimens. It is available in 19G, 22G, and 25G sizes. Key design features include a dual-beveled cutting tip to preserve tissue architecture, nitinol construction to maintain needle integrity in tortuous anatomy, and…
The American Gastroenterological Association has announced the AGA Tech Summit 2026, a flagship gathering designed to connect gastroenterologists, founders, investors, and industry leaders shaping the next generation of GI care. Scheduled for April 9–10, 2026 in Chicago, the summit will focus on the full innovation lifecycle—from early concept and validation to FDA strategy, reimbursement, and commercialization. Unlike traditional academic meetings, the Tech Summit is positioned as a hands-on forum for clinicians and entrepreneurs looking to translate ideas into real-world impact.
A recent feature in The Washington Post explores what could be the next frontier in obesity care: one-time gene therapies designed to replicate the metabolic effects of GLP-1 drugs without lifelong injections. While GLP-1 medications have driven unprecedented weight loss and market growth, a key limitation is durability—many patients discontinue treatment due to cost, side effects, or adherence challenges and subsequently regain weight. Researchers argue this drop-off undermines both clinical outcomes and long-term economic value. In response, several biotech efforts are pursuing gene therapies that permanently alter metabolic pathways, potentially delivering sustained appetite suppression or energy balance from a single…
A new scoping review covered by GI & Hepatology News highlights the growing potential of wearable technologies to transform how inflammatory bowel disease (IBD) is monitored and managed. Across 37 studies, researchers found that consumer wearables—such as smartwatches and fitness trackers—consistently captured meaningful changes in physical activity, sleep quality, heart rate, and heart rate variability that correlated with disease activity in Crohn’s disease and ulcerative colitis. In several longitudinal studies, physiologic changes appeared weeks before clinical flares, suggesting a role for earlier, more proactive intervention. Beyond consumer devices, early-stage biosensor patches showed promising correlations between sweat-based inflammatory markers (including CRP…